"Sitting them in both market places" is what I have thought Nuheara should have done. This snooty attitude of not getting involved in a race to the bottom for price was never a valid excuse for getting exclusively into hearing. You only need to look at Walmart after Googling OTC hearing on their website and 1000+ devices come up. Managements claim that they are competing with only a half dozen or so FDA approved devices is almost irrelevant. Sure most are not FDA approved, but there are many far cheaper than the HP Pro and which would serve the same purpose. Nuheara always has priced itself out of the market. Both !QMax 2 and HP Pro (technically similar) could also be competing in the general bluetooth, noise suppression, bud arena as well as in the hearing sector. To pivot all into an as yet undeveloped market when total sales were crucial to the survival of the company so far has not paid off.
- Forums
- ASX - By Stock
- NUH
- Ann: Suspension from Quotation
Ann: Suspension from Quotation, page-202
-
-
- There are more pages in this discussion • 323 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NUH (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.91M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
NUH (ASX) Chart |
Day chart unavailable